ClinicalTrials.gg
Active, not recruitingNCT03899792LIBRETTO-121Updated Jan 6, 2026Results posted

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

A Phase 1/2 interventional study of Selpercatinib in Medullary Thyroid Cancer, Infantile Myofibromatosis and Infantile Fibrosarcoma, sponsored by Eli Lilly and Company. Active, not recruiting at 26 sites in 11 countries. Open to participants aged 6 Months to 21 Years. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
6 Months to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Carcinoma, Medullary with a site in United States — 12 open to participants now, 24 under way, 1 of them phase 3. Carcinoma, Medullary · United States.

Enrollment
27th of 66
36 · median 30
Started
2019
with 3 others
Phase 1/2
11 of 81
1 open now
Primary completion
2024-11
later than 3 of 22 live
Registered
59th of 81
by date
Lead sponsor
3 of 81
Eli Lilly and Company

Among the 81 studies in Carcinoma, Medullary with a site in United States, this one is the 27th largest by enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2019, is one of 11 in phase 1/2, reaches primary completion later than 3 of the 22 other live ones, and was the 59th registered.

Carcinoma, Medullary

144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.

Browse Carcinoma, Medullary studies →

Open to participants now

12 of the 81 studies in Carcinoma, Medullary with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 6 Months to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Carcinoma, Medullary with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.

Read the detailed description

This study includes 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). In phase 1, participants will be enrolled using a rolling 6 dose escalation scheme. The starting dose of LOXO-292 is equivalent to the adult recommended phase 2 dose of 160 milligrams (mg) twice a day (BID). Once the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) is identified, participants will be enrolled to one of four phase 2 dose expansion cohorts depending on tumor histology and tumor genotype. Cycle length will be 28 days.

03

Conditions studied

  • Medullary Thyroid Cancer
  • Infantile Myofibromatosis
  • Infantile Fibrosarcoma
  • Papillary Thyroid Cancer
  • Soft Tissue Sarcoma

Keywords

  • Loxo
  • LOXO-292
  • KIF5B-RET
  • M918T
  • CCDC6-RET
  • RET-PTC1
  • NCOA4-RET
  • RET-PTC
  • RET-PTC3
  • RET-PTC4
  • PRKAR1A-RET
  • RET-PTC2
  • GOLGA5-RET
  • RET-PTC5
  • ERC1-RET
  • KTN1-RET
  • RET-PTC8
  • HOOK3-RET
  • PCM1-RET
  • TRIM24-RET
  • RET-PTC6
  • TRIM27-RET
  • TRIM33-RET
  • RET-PTC7
  • AKAP13-RET
  • FKBP15-RET
  • SPECC1L-RET
  • TBL1XR1-RET
  • BCR-RET
  • FGRF1OP-RET
  • RFG8-RET
  • RET-PTC9
  • ACBD5-RET
  • MYH13-RET
  • CUX1-RET
  • KIAA1468-RET
  • FRMD4A-RET
  • SQSTM1-RET
  • AFAP1L2-RET
  • PPFIBP2-RET
  • EML4-RET
  • PARD3-RET
  • G533C
  • C609F
  • C609G
  • C609R
  • C609S
  • C609Y
  • C611F
  • C611G
  • C611S
  • C611Y
  • C611W
  • C618F
  • C618R
  • C618S
  • C620F
  • C620R
  • C620S
  • C630R
  • C630Y
  • D631Y
  • C634F
  • C634G
  • C634R
  • C634S
  • C634W
  • C634Y
  • K666E
  • E768D
  • L790F
  • V804L
  • V804M
  • A883F
  • S891A
  • R912P
  • CLIP1-RET
  • Y806C
  • RET fusion
  • RET alteration
  • RET mutation
  • RET rearrangement
  • RET translocation
  • Neoplasms by Site
  • Neoplasms
  • Non-Small Cell Lung Cancer
  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Cancer of Lung
  • Cancer of the Lung
  • Lung Cancer
  • Neoplasms, Lung
  • Neoplasms, Pulmonary
  • Pulmonary Cancer
  • Pulmonary Neoplasms
  • Respiratory Tract Neoplasms
  • Lung Diseases
  • Respiratory Tract Diseases
  • Carcinoma, Bronchogenic
  • Bronchial Neoplasms
  • Medullary Thyroid Cancer
  • Papillary Thyroid Cancer
  • Thyroid Diseases
  • Thyroid Neoplasms
  • Cancer of the Thyroid
  • Cancer of Thyroid
  • Neoplasms, Thyroid
  • Thyroid Adenoma
  • Thyroid Cancer
  • Thyroid Carcinoma
  • Endocrine System Diseases
  • Endocrine Gland Neoplasms
  • Head and Neck Neoplasms
  • Thoracic Neoplasms
  • CNS tumor
  • Primary CNS tumor
  • Colonic Neoplasms
  • Cancer of Colon
  • Cancer of the Colon
  • Colon Cancer
  • Colon Neoplasms
  • Colonic Cancer
  • Neoplasms, Colonic
  • Malignant tumor of Breast
  • Mammary Cancer
  • Mammary Carcinoma, Human
  • Mammary Neoplasm, Human
  • Neoplasms, Breast
  • Tumors, Breast
  • Human Mammary Carcinoma
  • Malignant Neoplasm of Breast
  • Breast Carcinoma
  • Breast Tumors
  • Cancer of the Breast
  • Breast Neoplasms
  • Breast Cancer
  • RET Inhibitor
  • MTC
  • NSCLC
  • Soft tissue sarcoma
  • Infantile Myofibromatosis
  • Infantile Fibrosarcoma
04

Who can participate

Ages eligible
6 Months to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced or solid or primary CNS tumor which has failed standard of care therapies
  • Evidence of an activating RET gene alteration in the tumor and/or blood
  • Measurable or non-
  • (participants 16 years and older) or Lansky (participants younger than 16) performance score of at least 50
  • Participant with primary CNS tumors or cerebral metastases must be neurologically stable for 7 days prior and must not have required increasing doses of within the last 7 days
  • Adequate hematologic, hepatic and renal function.
  • Ability to receive study drug therapy orally or via gastric access
  • Willingness of men and women of to observe conventional and effective

Exclusion criteria

Exclusion Criteria:

  • Major surgery within two weeks prior to planned start of LOXO-292
  • , uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-292
  • Active uncontrolled systemic bacterial, viral, fungal or parasitic infection
  • Clinically significant active malabsorption syndrome
  • Pregnancy or lactation
  • Uncontrolled symptomatic hyperthyroidism or hypothyroidism (i.e. the participant required a modification to current thyroid medication in the 7 days before start of LOXO-292)
  • Uncontrolled symptomatic hypercalcemia or hypocalcemia
  • Known to any of the components of the agent, LOXO-292 or Ora-Sweet® SF and OraPlus®, for participants who will receive LOXO-292 suspension
  • Prior treatment with a selective RET inhibitor(s) (including investigational selective RET inhibitor[s])
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1: Medullary Thyroid Cancer (MTC) Group

    Participants in this cohort had MTC and received 160 mg of selpercatinib BID orally on Days 1 through 28 of a 28-day cycle. The treatment was continued until participants experienced a progressive disease, unacceptable toxicity, or other protocol-defined reason for discontinuation.

    Drug: Selpercatinib

  • Experimental
    Cohort 2: Papillary Thyroid Cancer (PTC) Group

    Participants in this cohort had PTC and received 160 mg of selpercatinib BID orally on Days 1 through 28 of a 28-day cycle. The treatment was continued until participants experienced a progressive disease, unacceptable toxicity, or other protocol-defined reason for discontinuation.

    Drug: Selpercatinib

  • Experimental
    Cohort 3: Other Cancer Group

    Participants in this cohort had other (REarranged during Transfection (RET)-altered non-thyroid) cancer and received 160 mg of selpercatinib BID orally on Days 1 through 28 of a 28-day cycle. The treatment was continued until participants experienced a progressive disease, unacceptable toxicity, or other protocol-defined reason for discontinuation.

    Drug: Selpercatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)

    A DLT was any of the adverse events that starts on or after the first administration of study drug listed below, as defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. * Any Grade(G) ≥3 nonhematologic toxicity except G3 fatigue, nausea, tendon reflex decrease, weight gain attributable to normal growth and development. * G3 vomiting/diarrhea was DLT only if it persists \>48 h despite standard of care treatment. * G4 vomiting/diarrhea was DLT regardless of duration. * Any toxicity, regardless of the NCI CTCAE v5.0 grade, resulting in discontinuation or dose reduction of treatment (except symptoms related to progressive disease (PD)). * G4/G3 thrombocytopenia with G1 or higher bleeding. * G4 anemia lasting \>8 days, despite supportive therapy. * G4 neutropenia, lasting \>8 days, despite supportive therapy

    Time frame: Cycle 1 (28 Day Cycle)

  2. Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study

    ORR: Percentage of participants who achieve best overall response Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST). * CR is defined as disappearance of all target lesions. * PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

    Time frame: Date of first dose to disease progression or death (Up to 62.4 Months)

Secondary outcomes

  1. Plasma Concentrations of LOXO-292

    Outcome data will be provided after the study is completed.

    Time frame: Days 1 and 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-participant Dose Escalation (each cycle is 28 days)

  2. Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of LOXO-292

    Outcome data will be provided after the study is completed.

    Time frame: Days 1 and 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-participant Dose Escalation (each cycle is 28 days)

  3. Maximum Concentration (Cmax) of LOXO-292

    Outcome data will be provided after the study is completed.

    Time frame: Days 1 and 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-participant Dose Escalation (each cycle is 28 days)

  4. Time to Maximum Concentration (Tmax) of LOXO-292

    Outcome data will be provided after the study is completed.

    Time frame: Days 1 and 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-participant Dose Escalation (each cycle is 28 days)

  5. Recommended LOXO-292 Dose for Phase 2 (MTD)

    Outcome data will be provided after the study is completed.

    Time frame: Cycle 1 (28 days)

  6. To Assess the Preliminary Anti-Tumor Activity of LOXO-292 in Pediatric Participants With Tumors Harboring an Activating RET Alteration as Determined by ORR Based on RECIST v1.1

    Outcome data will be provided after the study is completed.

    Time frame: Baseline to Progressive Disease or Death due to any cause (Estimated up to 12 months)

  7. Changes From Baseline in Pain Measures as Measured by Wong Baker Faces Scales. Wong-Baker Faces Pain Scale Includes Pictures of Facial Expressions With Correlating Scores of 0 Being 'no Hurt' and 10 Being 'Hurts Worst'.

    Outcome data will be provided after the study is completed.

    Time frame: Up to 24 months

  8. Changes From Baseline in Health Related Quality of Life Measures as Measured by Pediatric Quality of Life (PedsQoL) Inventory Core. PedsQoL Includes a List of Problems With Scores of 0 Being 'Never a Problem' and 4 Being 'Almost Always a Problem'.

    Outcome data will be provided after the study is completed.

    Time frame: Up to 24 months

  9. Objective Response Rate as Assessed by RECIST v1.1, as Assessed by Investigator

    Outcome data will be provided after the study is completed.

    Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

  10. Objective Response Rate as Assessed by RANO, as Assessed by Investigator

    Outcome data will be provided after the study is completed.

    Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

  11. Duration of Response (DOR) as Assessed by Investigator

    Outcome data will be provided after the study is completed.

    Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

  12. Duration of Response (DOR) as Assessed by the IRC

    Outcome data will be provided after the study is completed.

    Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

  13. Progression Free Survival (PFS) as Assessed by Investigator

    Outcome data will be provided after the study is completed.

    Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

  14. PFS as Assessed by IRC

    Outcome data will be provided after the study is completed.

    Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

  15. Overall Survival (OS)

    Outcome data will be provided after the study is completed.

    Time frame: Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

  16. Clinical Benefit Rate (by Investigator)

    Outcome data will be provided after the study is completed.

    Time frame: Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed.

  17. Clinical Benefit Rate (by IRC)

    Outcome data will be provided after the study is completed.

    Time frame: Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed.

  18. Frequency of Adverse Events (AEs)

    Outcome data will be provided after the study is completed.

    Time frame: From the time of informed consent, for approximately 24 months (or earlier if the participants discontinues from the study), and through Safety Follow-up (28 days after the last dose)

  19. To Evaluate the Concordance of Prior Molecular That Detected a RET Alteration Within the Participant's Tumor With Diagnostic Tests Being Evaluated by Sponsor

    Outcome data will be provided after the study is completed.

    Time frame: 6 months

  20. Phase 2: Post-Operative Stage on Participants Treated With LOXO-292

    Tumor stage is described according to the Tumor, Node, Metastasis (TNM)Classification of malignant tumors of the Union for International Cancer Control (UICC). Outcome data will be provided after the study is completed.

    Time frame: Up to 3 years

  21. Phase 2: Surgical Margin Status in Participants Treated With LOXO-292

    Tumor margins after surgery are classified into four groups using the International Cancer Control (UICC)-R classification and the Intergroup Rhabdomyosarcoma Staging (IRS) systems: 1) Complete tumor resection with histologically free margins, 2) Macroscopic resection but invaded margins on histology, 3)Macroscopic residual tumor and 4) Distant metastatic tumor. Outcome data will be provided after the study is completed.

    Time frame: Up to 3 years

  22. Descriptive Analysis of Pretreatment Surgical Plan

    Outcome data will be provided after the study is completed.

    Time frame: Up to 3 years

  23. Descriptive Analysis of Post-Treatment Plans

    Outcome data will be provided after the study is completed.

    Time frame: Up to 3 years

07

Results

Posted Jan 6, 2026

Participant flow

The study consisted of two parts: Phase 1 (dose-escalation) and Phase 2 (dose-expansion). In Phase 1, three participants received selpercatinib, with dosing based on body surface area. The starting dose level was 92 mg/m\^2 (maximum 160 mg, twice daily (BID\]), selected to approximate the exposure associated with the recommended Phase 2 dose (RP2D) in adults. The Phase 2 portion opened for enrollment after confirmation of the RP2D of 92 mg/m\^2 (maximum 160 mg BID).

Phase 1
Participant flow — Phase 1
MilestoneDose Escalation Cohort (Phase 1)Cohort 1 (Phase 2): Medullary Thyroid Cancer (MTC) GroupCohort 2 (Phase 2): Papillary Thyroid Cancer (PTC) GroupCohort 3 (Phase 2): Other Cancer Group
Started3000
Completed3000
Not completed0000
Phase 2
Participant flow — Phase 2
MilestoneDose Escalation Cohort (Phase 1)Cohort 1 (Phase 2): Medullary Thyroid Cancer (MTC) GroupCohort 2 (Phase 2): Papillary Thyroid Cancer (PTC) GroupCohort 3 (Phase 2): Other Cancer Group
Started015156
Received at least 1 dose of study drug015156
Completed0000
Not completed015156
Withdrew: Ongoing treatment013142
Withdrew: Death0004
Withdrew: Lost to follow-up0110
Withdrew: Withdrawal by subject0100

Outcome measures

PrimaryPhase 1: Number of Participants With Dose Limiting Toxicities (DLTs)

A DLT was any of the adverse events that starts on or after the first administration of study drug listed below, as defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. * Any Grade(G) ≥3 nonhematologic toxicity except G3 fatigue, nausea, tendon reflex decrease, weight gain attributable to normal growth and development. * G3 vomiting/diarrhea was DLT only if it persists \>48 h despite standard of care treatment. * G4 vomiting/diarrhea was DLT regardless of duration. * Any toxicity, regardless of the NCI CTCAE v5.0 grade, resulting in discontinuation or dose reduction of treatment (except symptoms related to progressive disease (PD)). * G4/G3 thrombocytopenia with G1 or higher bleeding. * G4 anemia lasting \>8 days, despite supportive therapy. * G4 neutropenia, lasting \>8 days, despite supportive therapy

Time frame:
Cycle 1 (28 Day Cycle)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsDose Escalation Cohort (Phase 1)
Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)0
PrimaryPhase 2: Percentage of Participants With Overall Response Rate (ORR) in Study

ORR: Percentage of participants who achieve best overall response Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST). * CR is defined as disappearance of all target lesions. * PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

Time frame:
Date of first dose to disease progression or death (Up to 62.4 Months)
Reported as:
Number · Percentage of participants
Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study
Percentage of participantsCohort 1 (Phase 2): MTC GroupCohort 2 (Phase 2): PTC GroupCohort 3 (Phase 2): Other Cancer Group
Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study60.053.333.3
SecondaryPlasma Concentrations of LOXO-292

Outcome data will be provided after the study is completed.

Time frame:
Days 1 and 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-participant Dose Escalation (each cycle is 28 days)

Results for this outcome have not been posted.

SecondaryArea Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of LOXO-292

Outcome data will be provided after the study is completed.

Time frame:
Days 1 and 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-participant Dose Escalation (each cycle is 28 days)

Results for this outcome have not been posted.

SecondaryMaximum Concentration (Cmax) of LOXO-292

Outcome data will be provided after the study is completed.

Time frame:
Days 1 and 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-participant Dose Escalation (each cycle is 28 days)

Results for this outcome have not been posted.

SecondaryTime to Maximum Concentration (Tmax) of LOXO-292

Outcome data will be provided after the study is completed.

Time frame:
Days 1 and 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-participant Dose Escalation (each cycle is 28 days)

Results for this outcome have not been posted.

SecondaryRecommended LOXO-292 Dose for Phase 2 (MTD)

Outcome data will be provided after the study is completed.

Time frame:
Cycle 1 (28 days)

Results for this outcome have not been posted.

SecondaryTo Assess the Preliminary Anti-Tumor Activity of LOXO-292 in Pediatric Participants With Tumors Harboring an Activating RET Alteration as Determined by ORR Based on RECIST v1.1

Outcome data will be provided after the study is completed.

Time frame:
Baseline to Progressive Disease or Death due to any cause (Estimated up to 12 months)

Results for this outcome have not been posted.

SecondaryChanges From Baseline in Pain Measures as Measured by Wong Baker Faces Scales. Wong-Baker Faces Pain Scale Includes Pictures of Facial Expressions With Correlating Scores of 0 Being 'no Hurt' and 10 Being 'Hurts Worst'.

Outcome data will be provided after the study is completed.

Time frame:
Up to 24 months

Results for this outcome have not been posted.

SecondaryChanges From Baseline in Health Related Quality of Life Measures as Measured by Pediatric Quality of Life (PedsQoL) Inventory Core. PedsQoL Includes a List of Problems With Scores of 0 Being 'Never a Problem' and 4 Being 'Almost Always a Problem'.

Outcome data will be provided after the study is completed.

Time frame:
Up to 24 months

Results for this outcome have not been posted.

SecondaryObjective Response Rate as Assessed by RECIST v1.1, as Assessed by Investigator

Outcome data will be provided after the study is completed.

Time frame:
Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

Results for this outcome have not been posted.

SecondaryObjective Response Rate as Assessed by RANO, as Assessed by Investigator

Outcome data will be provided after the study is completed.

Time frame:
Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) as Assessed by Investigator

Outcome data will be provided after the study is completed.

Time frame:
Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) as Assessed by the IRC

Outcome data will be provided after the study is completed.

Time frame:
Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

Results for this outcome have not been posted.

SecondaryProgression Free Survival (PFS) as Assessed by Investigator

Outcome data will be provided after the study is completed.

Time frame:
Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

Results for this outcome have not been posted.

SecondaryPFS as Assessed by IRC

Outcome data will be provided after the study is completed.

Time frame:
Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

Outcome data will be provided after the study is completed.

Time frame:
Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.

Results for this outcome have not been posted.

SecondaryClinical Benefit Rate (by Investigator)

Outcome data will be provided after the study is completed.

Time frame:
Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed.

Results for this outcome have not been posted.

SecondaryClinical Benefit Rate (by IRC)

Outcome data will be provided after the study is completed.

Time frame:
Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed.

Results for this outcome have not been posted.

SecondaryFrequency of Adverse Events (AEs)

Outcome data will be provided after the study is completed.

Time frame:
From the time of informed consent, for approximately 24 months (or earlier if the participants discontinues from the study), and through Safety Follow-up (28 days after the last dose)

Results for this outcome have not been posted.

SecondaryTo Evaluate the Concordance of Prior Molecular That Detected a RET Alteration Within the Participant's Tumor With Diagnostic Tests Being Evaluated by Sponsor

Outcome data will be provided after the study is completed.

Time frame:
6 months

Results for this outcome have not been posted.

SecondaryPhase 2: Post-Operative Stage on Participants Treated With LOXO-292

Tumor stage is described according to the Tumor, Node, Metastasis (TNM)Classification of malignant tumors of the Union for International Cancer Control (UICC). Outcome data will be provided after the study is completed.

Time frame:
Up to 3 years

Results for this outcome have not been posted.

SecondaryPhase 2: Surgical Margin Status in Participants Treated With LOXO-292

Tumor margins after surgery are classified into four groups using the International Cancer Control (UICC)-R classification and the Intergroup Rhabdomyosarcoma Staging (IRS) systems: 1) Complete tumor resection with histologically free margins, 2) Macroscopic resection but invaded margins on histology, 3)Macroscopic residual tumor and 4) Distant metastatic tumor. Outcome data will be provided after the study is completed.

Time frame:
Up to 3 years

Results for this outcome have not been posted.

SecondaryDescriptive Analysis of Pretreatment Surgical Plan

Outcome data will be provided after the study is completed.

Time frame:
Up to 3 years

Results for this outcome have not been posted.

SecondaryDescriptive Analysis of Post-Treatment Plans

Outcome data will be provided after the study is completed.

Time frame:
Up to 3 years

Results for this outcome have not been posted.

Adverse events

Collected over Baseline up to 64 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: MTC Group0/15 (0%)8/15 (53.3%)15/15 (100%)
Cohort 2: PTC Group0/15 (0%)4/15 (26.7%)15/15 (100%)
Cohort 3: Other Cancer Group4/6 (66.7%)3/6 (50%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventCohort 1: MTC GroupCohort 2: PTC GroupCohort 3: Other Cancer Group
Febrile neutropeniaBlood and lymphatic system disorders0/150/151/6
Gastrointestinal fistulaGastrointestinal disorders0/150/151/6
Drug hypersensitivityImmune system disorders0/150/151/6
Abdominal infectionInfections and infestations0/150/151/6
SepsisInfections and infestations0/150/151/6
VomitingGastrointestinal disorders2/150/150/6
Abdominal painGastrointestinal disorders1/150/150/6
AscitesGastrointestinal disorders0/151/150/6
ConstipationGastrointestinal disorders1/150/150/6
DiarrhoeaGastrointestinal disorders1/150/150/6
Most frequent other events
Showing 10 of 293
Most frequent other events
EventCohort 1: MTC GroupCohort 2: PTC GroupCohort 3: Other Cancer Group
DiarrhoeaGastrointestinal disorders5/1510/152/6
VomitingGastrointestinal disorders9/152/150/6
NauseaGastrointestinal disorders8/155/151/6
Upper respiratory tract infectionInfections and infestations8/152/150/6
Aspartate aminotransferase increasedInvestigations3/158/153/6
ArthralgiaMusculoskeletal and connective tissue disorders8/152/150/6
HeadacheNervous system disorders8/154/150/6
Abdominal painGastrointestinal disorders4/154/153/6
PyrexiaGeneral disorders7/154/153/6
Alanine aminotransferase increasedInvestigations4/155/153/6

Baseline characteristics

All participants who received at least one dose of study drug. The Baseline data were planned to be presented according to Phases. Here "number analyzed" signifies participants who were evaluable for specified Phase of the study.

Age, Customized
Age, Customized(Participants)Dose Escalation Cohort (Phase 1)Cohort 1 (Phase 2): MTC GroupCohort 2 (Phase 2): PTC GroupCohort 3 (Phase 2): Other Cancer GroupTotal
Age — <=18 years21013530
Age — Between 18 and 65 years13206
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation Cohort (Phase 1)Cohort 1 (Phase 2): MTC GroupCohort 2 (Phase 2): PTC GroupCohort 3 (Phase 2): Other Cancer GroupTotal
Female257317
Male188219
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Escalation Cohort (Phase 1)Cohort 1 (Phase 2): MTC GroupCohort 2 (Phase 2): PTC GroupCohort 3 (Phase 2): Other Cancer GroupTotal
Hispanic or Latino30407
Not Hispanic or Latino01111426
Unknown or Not Reported02013
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Escalation Cohort (Phase 1)Cohort 1 (Phase 2): MTC GroupCohort 2 (Phase 2): PTC GroupCohort 3 (Phase 2): Other Cancer GroupTotal
American Indian or Alaska Native00000
Asian007310
Native Hawaiian or Other Pacific Islander00000
Black or African American02002
White396018
More than one race00000
Unknown or Not Reported02226
Region of Enrollment
Region of Enrollment(Participants)Dose Escalation Cohort (Phase 1)Cohort 1 (Phase 2): MTC GroupCohort 2 (Phase 2): PTC GroupCohort 3 (Phase 2): Other Cancer GroupTotal
Canada02215
South Korea00426
United States334111
Japan00213
Denmark01001
Italy00202
France01001
Australia04004
Germany02002
Spain00101
08

Study locations

26 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Nov 2024, 64 months.

Results were first posted in Jan 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2019
First posted
Apr 2, 2019
StartActual
Jun 13, 2019
Primary completionActual
Nov 8, 2024
CompletionEst.
May 2029
Results first posted
Jan 6, 2026
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03899792
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Apr 2, 2019
Start date
Jun 13, 2019
Primary completion
Nov 8, 2024
Completion
May 2029 (estimated)
Results posted
Jan 6, 2026
Last update
Jan 6, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion